LENZ Therapeutics Inc Asset Resilience Ratio
LENZ Therapeutics Inc asset resilience ratio. LENZ Therapeutics Inc (LENZ) has an Asset Resilience Ratio of 82.75% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LENZ Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of LENZ Therapeutics Inc (2023–2025)
Asset resilience ratio of LENZ Therapeutics Inc from 2023 to 2025. This chart shows how LENZ Therapeutics Inc's Asset Resilience Ratio has changed over time. Read debt load of LENZ Therapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down LENZ Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LENZ Therapeutics Inc balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $195.79 Million | 82.75% |
| Total Liquid Assets | $195.79 Million | 82.75% |
Asset Resilience Insights
- Very High Liquidity: LENZ Therapeutics Inc maintains exceptional liquid asset reserves at 82.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
LENZ Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare LENZ Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
LENZ Therapeutics Inc Asset Resilience Ratio by Year (2023–2025)
LENZ Therapeutics Inc asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for LENZ Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 87.35% | $267.17 Million | $305.88 Million | -0.38pp |
| 2024-12-31 | 87.72% | $188.87 Million | $215.30 Million | +44.17pp |
| 2023-12-31 | 43.56% | $30.65 Million | $70.38 Million | -- |
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2… Read more